Literature DB >> 11413294

Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles.

C L Day1, A K Shea, M A Altfeld, D P Olson, S P Buchbinder, F M Hecht, E S Rosenberg, B D Walker, S A Kalams.   

Abstract

Cytotoxic T lymphocytes (CTL) target multiple epitopes in human immunodeficiency virus (HIV)-infected persons, and are thought to influence the viral set point. The extent to which HLA class I allele expression predicts the epitopes targeted has not been determined, nor have the relative contributions of responses restricted by different class I alleles within a given individual. In this study, we performed a detailed analysis of the CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7. The eight HIV-1-infected subjects studied included two subjects with acute HIV infection, five subjects with chronic HIV infection, and one long-term nonprogressor. Responses were heterogeneous with respect to breadth and magnitude of CTL responses in individuals of the same HLA type. Of the 27 tested epitopes that are presented by A2, A3, and B7, 25 were targeted by at least one person. However, there was wide variation in the number of epitopes targeted, ranging from 2 to 17. The A2-restricted CTL response, which has been most extensively studied in infected persons, was found to be narrowly directed in most individuals, and in no cases was it the dominant contributor to the total HIV-1-specific CTL response. These results indicate that HLA type alone does not predict CTL responses and that numerous potential epitopes may not be targeted by CTL in a given individual. These data also provide a rationale for boosting both the breadth and the magnitude of HIV-1-specific CTL responses by immunotherapy in persons with chronic HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413294      PMCID: PMC114350          DOI: 10.1128/JVI.75.14.6279-6291.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.

Authors:  P J Goulder; R E Phillips; R A Colbert; S McAdam; G Ogg; M A Nowak; P Giangrande; G Luzzi; B Morgan; A Edwards; A J McMichael; S Rowland-Jones
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

2.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.

Authors:  N V Sipsas; S A Kalams; A Trocha; S He; W A Blattner; B D Walker; R P Johnson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

4.  Structural constraints of HIV-1 Nef may curtail escape from HLA-B7-restricted CTL recognition.

Authors:  M Bauer; M Lucchiari-Hartz; R Maier; G Haas; B Autran; K Eichmann; R Frank; B Maier; A Meyerhans
Journal:  Immunol Lett       Date:  1997-02       Impact factor: 3.685

5.  Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays.

Authors:  P J Goulder; M M Addo; M A Altfeld; E S Rosenberg; Y Tang; U Govender; N Mngqundaniso; K Annamalai; T U Vogel; M Hammond; M Bunce; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo.

Authors:  G Haas; U Plikat; P Debré; M Lucchiari; C Katlama; Y Dudoit; O Bonduelle; M Bauer; H G Ihlenfeldt; G Jung; B Maier; A Meyerhans; B Autran
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

7.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.

Authors:  D A Price; P J Goulder; P Klenerman; A K Sewell; P J Easterbrook; M Troop; C R Bangham; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

8.  Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences.

Authors:  C Brander; O O Yang; N G Jones; Y Lee; P Goulder; R P Johnson; A Trocha; D Colbert; C Hay; S Buchbinder; C C Bergmann; H J Zweerink; S Wolinsky; W A Blattner; S A Kalams; B D Walker
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype.

Authors:  M R Betts; J P Casazza; B A Patterson; S Waldrop; W Trigona; T M Fu; F Kern; L J Picker; R A Koup
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

Authors:  P J Goulder; A K Sewell; D G Lalloo; D A Price; J A Whelan; J Evans; G P Taylor; G Luzzi; P Giangrande; R E Phillips; A J McMichael
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

View more
  18 in total

1.  Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire.

Authors:  Dirk Meyer-Olson; Kristen W Brady; Melissa T Bartman; Kristin M O'Sullivan; Brenna C Simons; Joseph A Conrad; Coley B Duncan; Shelly Lorey; Atif Siddique; Rika Draenert; Marylyn Addo; Marcus Altfeld; Eric Rosenberg; Todd M Allen; Bruce D Walker; Spyros A Kalams
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

2.  Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins.

Authors:  Otto O Yang; Joseph Church; Christina M R Kitchen; Ryan Kilpatrick; Ayub Ali; Yongzhi Geng; M Scott Killian; Rachel Lubong Sabado; Hwee Ng; Jeffrey Suen; Yvonne Bryson; Beth D Jamieson; Paul Krogstad
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.

Authors:  Irena Kiszka; Dariusz Kmieciak; Jaroslaw Gzyl; Toshio Naito; Elizabeth Bolesta; Aleksander Sieron; Satya P Singh; Alagarsamy Srinivasan; Giorgio Trinchieri; Yutaro Kaneko; Danuta Kozbor
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities.

Authors:  Georg M Lauer; Kei Ouchi; Raymond T Chung; Tam N Nguyen; Cheryl L Day; Deborah R Purkis; Markus Reiser; Arthur Y Kim; Michaela Lucas; Paul Klenerman; Bruce D Walker
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.

Authors:  Karina Yusim; Can Kesmir; Brian Gaschen; Marylyn M Addo; Marcus Altfeld; Søren Brunak; Alexandre Chigaev; Vincent Detours; Bette T Korber
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Maintenance or emergence of chronic phase secondary cytotoxic T lymphocyte responses after loss of acute phase immunodominant responses does not protect SIV-infected rhesus macaques from disease progression.

Authors:  M Shannon Keckler; Vida L Hodara; Laura M Parodi; Luis D Giavedoni
Journal:  J Biomed Biotechnol       Date:  2010-05-25

7.  Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells.

Authors:  Marybeth Daucher; David A Price; Jason M Brenchley; Laurie Lamoreaux; Julia A Metcalf; Catherine Rehm; Elizabeth Nies-Kraske; Elizabeth Urban; Christian Yoder; Diane Rock; Julie Gumkowski; Michael R Betts; Mark R Dybul; Daniel C Douek
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

8.  Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef.

Authors:  Maria Lucchiari-Hartz; Viv Lindo; Niclas Hitziger; Simone Gaedicke; Loredana Saveanu; Peter M van Endert; Fiona Greer; Klaus Eichmann; Gabriele Niedermann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-16       Impact factor: 11.205

9.  Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

Authors:  M M Addo; X G Yu; A Rathod; D Cohen; R L Eldridge; D Strick; M N Johnston; C Corcoran; A G Wurcel; C A Fitzpatrick; M E Feeney; W R Rodriguez; N Basgoz; R Draenert; David R Stone; C Brander; P J R Goulder; E S Rosenberg; M Altfeld; B D Walker
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.